We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells.
- Authors
LEI JIANG; YI-MING ZHAO; MING-ZHEN YANG
- Abstract
Bortezomib is a novel proteasome inhibitor, which has been successfully used to treat mantle cell lymphoma and multiple myeloma. However, the direct effects of bortezomib on acute promyelocytic leukaemia (APL) have not been fully investigated. In the present study, the WST-8 assay, western blotting, flow cytometry, monodansylcadaverine staining and transmission electron microscopy were performed. It was demonstrated that bortezomib treatment induced a timeand dose-dependent decrease in the viability of NB4 cells. Bortezomib treatment induced cell apoptosis in NB4 cells, as assessed by Annexin V/propidium iodide analysis, and the detection of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, Bax and Bcl-2 expression. Furthermore, bortezomib treatment induced autophagy in NB4 cells, as indicated by autophagosome formation, p62 degradation, LC3-I to LC3-II conversion and formation of acidic autophagic vacuoles. Notably, autophagy induced by bortezomib was initiated prior to apoptosis. Inhibition of autophagy by knocking down Beclin-1 expression increased bortezomib-induced apoptosis in NB4 cells. Therefore, the present study revealed that the combination of bortezomib and autophagy inhibition may be a potential treatment strategy for APL.
- Subjects
BORTEZOMIB; ACUTE promyelocytic leukemia; AUTOPHAGY; MANTLE cell lymphoma; PROTEASOME inhibitors; ACUTE myeloid leukemia
- Publication
Oncology Letters, 2021, Vol 21, Issue 2, p1
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2020.12370